Interferon alpha-n1

Drug Profile

Interferon alpha-n1

Alternative Names: Wellferon

Latest Information Update: 06 Nov 2015

Price : $50

At a glance

  • Originator Glaxo Wellcome SA
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hepatitis C
  • Market Withdrawal Cancer; Chronic myeloid leukaemia; Condylomata acuminata; Hairy cell leukaemia; Hepatitis B; Recurrent respiratory papillomatosis

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top